Clinical trials: Margin Assessment
Inflammation, Burns
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
The purpose of this study is to evaluate the change in signs of inflammation/local infection when Mepilex Border Ag is used in normal clinical practice when used on chronic ulcers (venous leg, diabetic foot and pressure ulcers)…
- Conditions
- Inflammation, Burns, Ulcers
- Trial name
- NCT01214811
- Testing
- Mepilex Border Ag
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Molnlycke Health Care AB
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
- Trial name
- NCT02924402
- Testing
- XmAb13676
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 154 people
- Sponsor
- Xencor, Inc.
Surgical Wound
A Post-Market Clinical Investigation on Mepilex Border Post-Op
This is a retrospective, observational (non-interventional), single-arm, single-centre, post-market clinical investigation designed to verify clinical performance and safety of Mepilex Border Post-Op when used according to…
- Trial name
- ARCTIS (NCT04994145)
- Where
- Belgium
- Volunteers
- 560 people
- Sponsor
- Molnlycke Health Care AB
Jaw, Edentulous, Partially
Study to Evaluate Implant Survival Rate of Astra Tech Fixture ST in the Posterior Maxilla With One-stage Surgery and Early Loading
The purpose of this study is primarily to evaluate implant survival rate of Astra Tech Fixture ST placed in the posterior maxilla.
- Trial name
- NCT00748241
- Testing
- Astra Tech Fixture ST
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dentsply Sirona Implants and Consumables
CLL/SLL, Waldenstrom Macroglobulinemia
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies.
- Conditions
- CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT04775745
- Testing
- LP-168
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Newave Pharmaceutical Inc
Mucopolysaccharidosis (MPS), Hunter Syndrome
Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)
Hunter syndrome (Mucopolysaccharidosis II, [MPS II]) is a rare, genetically linked lysosomal storage disease (LSD) caused by deficiency of the enzyme, iduronate-2-sulfatase (I2S).
- Trial name
- NCT01822184
- Where
- 7 sites in United States, Argentina and 3 more
- Volunteers
- 100 people
- Sponsor
- Shire
Marginal Bone Level Change
A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components
This is a multicenter, prospective, non-interventional study in which a total of 1000 subjects in need of a single, multiple or full arch restoration in any region of the mouth (healed or extracted) will be treated in up to 30…
- Trial name
- NCT04737421
- Testing
- NobelActive TiUltra implant, NobelParallel CC TiUltra implants, NobelReplace CC TiUltra implants
- Where
- 32 sites in United States, Australia and 12 more
- Volunteers
- 1,000 people
- Sponsor
- Nobel Biocare
Relapsed/Refractory B-cell Malignancies
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: Identify the recommended dose of AC676 that can be given safely to…
- Trial name
- NCT05780034
- Testing
- AC676
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Accutar Biotechnology Inc
Relapsed/Refractory Marginal Zone Lymphoma
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
- Trial name
- NCT06082102
- Testing
- Orelabrutinib, Rituximab, Lenalidomide
- Where
- 19 sites in China
- Volunteers
- 324 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Breast Cancer
MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery
The purpose of this study is to show that addition of device use to a routine breast cancer tumor excision procedure is beneficial and assists the surgeon in correctly determining the extent of excision.
- Trial name
- Pivotal (NCT00749931)
- Testing
- MarginProbe, Lumpectomy
- Where
- 21 sites in United States, Israel
- Volunteers
- 664 people
- Sponsor
- Dune Medical Devices
B-cell Lymphoma
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
B-cell cancer is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- NCT04804254
- Testing
- ABBV-623, ABBV-992
- Where
- 5 sites in Israel, Puerto Rico and 1 more
- Volunteers
- 5 people
- Sponsor
- AbbVie
Breast Cancer
Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry
This is a minimal risk post-market registry study conducted at participating clinical institutions that are utilizing LumiSystem consistent with the U.S.
- Trial name
- IMPACT (NCT07616856)
- Where
- 2 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Lumicell, Inc.
Prostatic Neoplasms
PRIME - PRostate Imaging for Margin Evaluation
This study will evaluate the feasibility of using intra-operative Cerenkov Luminescence Imaging (CLI) of prostatectomy specimens to determine tumour margin status.
- Trial name
- PRIME (NCT02151097)
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Lightpoint Medical Limited
Edentulous
A Clinical Evaluation of NobelProcera Implant Bar Overdenture
AN OPEN 5-YEAR PROSPECTIVE, CLINICAL MULTI-CENTER STUDY on NobelProcera Implant Bar Titanium with Locator attachment and related Overdenture on 4 NobelReplace implants with conical connection (CC) in the mandible/maxilla.
- Trial name
- NCT01720420
- Testing
- NobelReplace CC, NobelProcera Implant Bar
- Where
- 7 sites in Germany, Italy
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Nobel Biocare
Black Triangles Syndrome (BTS), Periodontal Gingival Contraction
Evaluation of the Safety and Performance of the Medical Device RDM36 in the Treatment of Periodontal Gingival Contraction and in Black Triangles Syndrome (BTS)
The treatment of black triangles in modern dentistry involves various approaches, both surgical and nonsurgical. Surgical methods aim to reconstruct or preserve gingival tissue using techniques such as soft tissue flaps or…
- Trial name
- NCT07185191
- Testing
- RDM36, Saline Solution (NaCl 0,9%)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Mastelli S.r.l
LIVER TRANSPLANTATION
Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts
The purpose of the study is to compare the safety and efficacy of two different tacrolimus based immunosuppressive regimens, one in combination with daclizumab, the other in combination with steroids, in recipients of suboptimal…
- Trial name
- PANTERA (NCT00321074)
- Testing
- TACROLIMUS
- Where
- 9 sites in Italy
- Volunteers
- 101 people
- Sponsor
- Astellas Pharma Inc
MZL
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be…
- Trial name
- NCT03797456
- Testing
- ICP-022
- Where
- 32 sites in China
- Volunteers
- 111 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Follicular Lymphoma, Marginal Zone Lymphoma
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an…
- Trial name
- InMIND (NCT04680052)
- Testing
- tafasitamab, rituximab, lenalidomide
- Where
- 261 sites in United States, Australia and 26 more
- Volunteers
- 654 people
- Sponsor
- Incyte Corporation
Breast Cancer
Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)
This multi-center, prospective, open label study analyzed specimens from fifty subjects at two study sites. Patients scheduled to undergo breast-conserving surgery were recruited in accordance with the inclusion and exclusion…
- Trial name
- NCT01699867
- Testing
- Optical coherence tomography
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Diagnostic Photonics, Inc.
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics